Drug Target Review explores why researchers at Racura Oncology are taking a fresh look at bisantrene, an anticancer drug first developed decades ago but later abandoned before reaching full clinical potential. The article highlights how modern molecular tools have revealed new mechanistic insights that were previously inaccessible, including evidence that bisantrene may suppress MYC, one of oncology’s most challenging targets, through interactions with G‑quadruplex DNA structures.

These findings have prompted renewed interest from biotech innovators who see value in revisiting discontinued compounds with strong biological rationale and known safety profiles. With new data emerging from preclinical studies and early clinical programmes, bisantrene is becoming a case study in how legacy molecules can be re‑evaluated and repurposed using today’s more advanced understanding of cancer biology.

Read the full story here.